TRPC6 and pancreatic neoplasm: Similarly, the CXCR2-dependent recruitment of neutrophil granulocytes to the stroma of pancreatic cancer where they elicit high immunosuppressive activity and drive disease progression [57] could potentially be targeted by TRPC6 blockers.